


176

What is claimed is:

1. A compound of formula (I):



including salts, solvates, and pharmacologically functional derivatives thereof

5 wherein

R^1 is OH;

each of R^2 and R^4 independently are selected from OH, alkyl, or halogen;

each of p and q independently are selected from 0, 1, or 2;

R^3 is $-(Y)_z-R^8$;

10 z is 0 or 1;

Y is $-C\equiv C-$ or $-CR^e=CR^f-$;

X is $-(CH_2)_n-$ where n is 0, 1, 2, or 3, $-C(R^g)_2-$, $-O-$, or $-S-$;

each R^6 is H; or

15 both R^5 s together combine to form a bridging alkylene chain $-(CH_2)_m-$, where m is 2, 3, or 4, when each R^6 and each R^7 is H and X is $-(CH_2)_{m-2}-$;

each of R^6 and R^7 are selected from H or alkyl; or

20 X is $-(CH_2)_m-$, both R^6 s are H, and both R^7 s together combine to form a bridging alkylene chain $-(CH_2)_m-$, where each m is the same and is as defined; or

X is $-(CH_2)_m-$, both R^7 s are H, and both R^6 s together combine to form a bridging alkylene chain $-(CH_2)_m-$, where each m is the same and is as defined;

when z is 0, then R^8 is alkyl, halogen, alkoxy, aryl, heteroaryl, heterocyclyl, cyano,

25 $-O(R^h)_lCN$, $-CO_2H$, $-(R^h)_lCO_2H$, $-O(R^h)_lCO_2H$, $-(R^h)_lOH$, $-O(R^h)_lOH$, $-O(R^h)_lO(R^h)_lOH$, $-CONR^aR^b$, $-SO_2R^d$, $-NR^aSO_2R^d$, $-COR^c$, or $-NR^aCOR^c$;

when z is 1, then R^8 is $-CO_2H$, $-(R^h)_tCO_2H$, $-(R^h)_tOH$, $-CONR^aR^b$, or $-PO_3HR^a$; or
 when z is 1, and Y is $-C\equiv C-$, then R^8 may also be H;

t is 1 to 8;

5

R^a is H, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

R^b is H, alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

R^c is alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl;

R^d is alkyl, cycloalkyl, aryl, heteroaryl, or heterocyclyl; or

10 R^a and R^b , R^a and R^c , or R^a and R^d may combine with the atoms to which they are bound to form a heteroaryl or heterocyclyl ring; and

R^e and R^f each are independently selected from H, alkyl, halogen, and haloalkyl;

R^g is alkyl;

each R^h independently is $-CR^lR^k-$, where each of R^l and R^k independently are

15 selected from H and alkyl;

wherein each occurrence of alkyl, cycloalkyl, aryl, heteroaryl, and heterocyclyl may be optionally substituted.

- 20 2. The compound of claim 1 wherein alkyl is C_{1-8} alkyl, alkoxy is C_{1-8} alkoxy, alkenyl is C_{2-8} alkenyl, and alkynyl is C_{2-8} alkynyl.
3. The compound of claim 1 wherein R^1 is substituted para on the depicted ring.
4. The compound of claim 1 wherein p and q each are 0.
5. The compound of claim 1 wherein z is 1, Y is $-CR^e=CR^f-$, and R^8 is $-CO_2H$.
- 25 6. The compound of claim 5 wherein R^e and R^f are H or C_{1-8} alkyl.
7. The compound of claim 1 wherein z is 1, Y is $-CR^e=CR^f-$, and R^8 is $-C(O)NR^aR^b$.
8. The compound of claim 7 wherein R^a and R^b each are H.
9. The compound of claim 1 wherein z is 1, Y is $-C\equiv C-$, and R^8 is $-CO_2H$, $-(R^h)_tCO_2H$, or $-(CH_2)_tOH$.
- 30 10. The compound of claim 1 wherein each of R^6 and R^7 are H or C_{1-8} alkyl.
11. The compound of claim 1 wherein X is $-(CH_2)_n-$.
12. The compound of claim 11 wherein n is 1.
13. The compound of claim 12 wherein R^6 and R^7 are alkyl.
- 35 14. The compound of claim 11 wherein n is 2 or 3.

15. The compound of claim 14 wherein R⁶ and R⁷ are hydrogen.
16. The compound of claim 1 wherein X is -O-.
17. The compound of claim 16 wherein R⁶ and R⁷ are alkyl.
18. The compound of claim 1 wherein z is 0 and R⁸ is -CO₂H, -NR^aSO₂R^d, aryl,
5 or heteroaryl.
19. The compound of claim 18 wherein R⁸ is phenyl, optionally substituted with one or more of cyano, halogen, heterocyclyl, -CO₂H, -(R^h)₁OH, -SO₂R^d, -C(O)NR^aR^b, -NR^aCOR^c, -NR^aSO₂R^d, and -CH=CH-CO₂H.
20. The compound of claim 19 wherein R^a is H, R^b is H, R^c is alkyl, and R^d is
10 alkyl.
21. The compound of claim 18 wherein R⁸ is -CO₂H.
22. The compound of claim 18 wherein R⁸ is -NR^aSO₂R^d, R^a is H, and R^d is alkyl or aryl.
23. The compound of claim 18 wherein R⁸ is isooxazolyl, oxazolyl, pyrimidyl,
15 pyridyl, or furyl.
24. The compound of claim 1 wherein R⁸ is -CONR^aR^b, and R^a and R^b combine to form a 5 or 6 membered heterocyclyl ring optionally substituted with -CO₂H.
25. The compound of claim 1 selected from:
(2E)-3-{4-[Cyclopentylidene(4-hydroxyphenyl)methyl]phenyl}-2-propenoic acid;
20 (2E)-3-{4-[Cyclohexylidene(4-hydroxyphenyl)methyl]phenyl}-2-propenoic acid;
(2E)-3-{4-[Cycloheptylidene(4-hydroxyphenyl)methyl]phenyl}-2-propenoic acid;
(2E)-3-{4-[Cyclohexylidene(4-hydroxyphenyl)methyl]phenyl}-2-propenamide;
(2E)-3-{4-[Cycloheptylidene(4-hydroxyphenyl)methyl]phenyl}-2-propenamide;
(2E)-3-{4-[(4-Hydroxyphenyl)(3,3,5,5-tetramethylcyclohexylidene) methyl]phenyl}-2-
25 propenoic acid;
(2E)-3-{4-[(4-Hydroxyphenyl)(3,3,5,5-tetramethylcyclohexylidene) methyl]phenyl}-2-
propenamide;
4-[[4-(1H-Pyrrol-2-yl)phenyl](3,3,5,5-tetramethylcyclohexylidene)methyl]phenol;
(2E)-3-{4-[(4,4-Dimethylcyclohexylidene)(4-hydroxyphenyl)methyl]phenyl}-2-
30 propenoic acid;
4-[(4-Hydroxyphenyl)(3,3,5,5-tetramethylcyclohexylidene) methyl]benzoic acid;
(2E)-3-{4-[Cyclohexylidene(4-hydroxy-2-methylphenyl)methyl]phenyl}-2-propenoic
acid;
(2E)-3-{4-[cyclohexylidene(4-hydroxy-3-methylphenyl)methyl]phenyl}-2-propenoic
35 acid;

- (2E)-3-{4-[(4-Hydroxyphenyl)(tetrahydro-4H-thiopyran-4-ylidene)methyl]phenyl}-2-propenoic acid;
- 1-((2E)-3-{4-[Cycloheptylidene(4-hydroxyphenyl)methyl]phenyl}-2-propenoyl)-3-piperidinecarboxylic acid;
- 5 1-((2E)-3-{4-[Cycloheptylidene(4-hydroxyphenyl)methyl]phenyl}-2-propenoyl)-4-piperidinecarboxylic acid;
- 1-((2E)-3-{4-[Cycloheptylidene(4-hydroxyphenyl)methyl]phenyl}-2-propenoyl)proline;
- (2E)-3-{4-[bicyclo[3.3.1]non-9-ylidene(4-hydroxyphenyl)methyl]phenyl}-2-propenoic acid;
- 10 (2E)-3-{4-[(4-hydroxyphenyl)(tetrahydro-4H-pyran-4-ylidene)methyl]phenyl}prop-2-enoic acid;
- (2E)-3-{4-[Cyclooctylidene(4-hydroxyphenyl)methyl]phenyl}prop-2-enoic acid;
- (2E)-3-{4-[(4-Hydroxyphenyl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylidene)methyl]phenyl}prop-2-enoic acid;
- 15 N-{4-[(4-hydroxyphenyl)(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl}acetamide;
- (2E)-3-{4-[(4-hydroxyphenyl)(tetrahydro-4H-pyran-4-ylidene)methyl]phenyl}-2-methylprop-2-enoic acid;
- 4-[[4-[(2-[(2-Hydroxyethyl)oxy]ethyl)oxy]phenyl](3,3,5,5-
- 20 tetramethylcyclohexylidene)methyl]phenol;
- Ethyl hydrogen (E)-2-{4-[cycloheptylidene(4-hydroxyphenyl)methyl]phenyl}ethenylphosphonate;
- (2E)-3-{4-[Cyclohexylidene(4-hydroxyphenyl)methyl]-2-methylphenyl}-2-propenoic acid;
- 25 (2E)-3-{3-Chloro-4-[cyclohexylidene(4-hydroxyphenyl)methyl]phenyl}-2-propenoic acid;
- (2E)-3-{4-[Cyclohexylidene(4-hydroxyphenyl)methyl]-3-fluorophenyl}-2-propenoic acid;
- (2E)-3-{4-[Cyclohexylidene(3-fluoro-4-hydroxyphenyl)methyl]phenyl}-2-propenoic acid;
- 30 (2E)-3-{4-[Cyclohexylidene(4-hydroxyphenyl)methyl]-2-fluorophenyl}-2-propenoic acid;
- 4-[[4-(Methylsulfonyl)phenyl](3,3,5,5 tetramethylcyclohexylidene)methyl]phenol;
- 4-[(4-hydroxyphenyl)(3,3,5,5-tetramethylcyclohexylidene)methyl]benzamide;
- 35 4-[[4-[(2-Hydroxyethyl)oxy]phenyl](3,3,5,5-tetramethylcyclohexylidene)methyl]phenol;


- 4'-[(4-Hydroxyphenyl)(3,3,5,5-tetramethylcyclohexylidene)methyl]-3-biphenylcarboxylic acid;
- 4'-[(4-Hydroxyphenyl)(3,3,5,5-tetramethylcyclohexylidene)methyl]-4-biphenylcarboxylic acid;
- 5 (2E)-3-{4-[(3-Chloro-4-hydroxyphenyl)(cyclohexylidene)methyl]phenyl}-2-propenoic acid;
- (2E)-3-{4-[Cyclohexylidene(2-fluoro-4-hydroxyphenyl)methyl]phenyl}-2-propenoic acid;
- (2E)-3-{4-[Cyclohexylidene(4-hydroxy-2,3-dimethylphenyl)methyl]phenyl}-2-
- 10 propenoic acid;
- (2E)-3-{4-[Cyclohexylidene(2,3-difluoro-4-hydroxyphenyl)methyl]phenyl}-2-propenoic acid;
- (2E)-3-{4-[(3-Chloro-4-hydroxyphenyl)(cycloheptylidene) methyl] phenyl}-2-propenoic acid;
- 15 (2E)-3-{4-[(3-Chloro-4-hydroxyphenyl)(3,3,5,5-tetramethylcyclohexylidene) methyl] phenyl}-2-propenoic acid;
- (2E)-3-{4-[(3-Chloro-4-hydroxyphenyl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylidene) methyl] phenyl}-2-propenoic acid;
- (2E)-3-{4-[(3-fluoro-4-hydroxyphenyl)(cycloheptylidene) methyl] phenyl}-2-propenoic
- 20 acid;
- (2E)-3-{4-[(3-fluoro-4-hydroxyphenyl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylidene) methyl] phenyl}-2-propenoic acid;
- (2E)-3-{4-[(3-fluoro-4-hydroxyphenyl)(3,3,5,5-tetramethylcyclohexylidene) methyl] phenyl}-2-propenoic acid;
- 25 4-{[4-(3-hydroxy-1-propyn-1-yl)phenyl](3,3,5,5-tetramethylcyclohexylidene) methyl]phenol};
- 4-{[4-Ethynylphenyl](3,3,5,5-tetramethylcyclohexylidene)methyl]phenol};
- 3-{4-[(4-Hydroxyphenyl)(3,3,5,5-tetramethylcyclohexylidene)methyl] phenyl}-2-propynoic acid;
- 30 {4-[(4-Hydroxyphenyl)(3,3,5,5-tetramethylcyclohexylidene)methyl] phenyl} acetic acid;
- 4-[Cycloheptylidene(4-hydroxyphenyl)methyl]benzoic acid;
- 4-[Cyclohexylidene(4-hydroxyphenyl)methyl]benzoic acid;
- 4-[Cyclooctylidene(4-hydroxyphenyl)methyl]benzoic acid;
- 35 4-{[4-(1,3-Oxazol-2-yl)phenyl](3,3,5,5-tetramethylcyclohexylidene)methyl]phenol};

- 4'-[(4-Hydroxyphenyl)(3,3,5,5-tetramethylcyclohexylidene)methyl]-3-biphenylcarboxamide;
 4-[[4-(5-Pyrimidinyl)phenyl](3,3,5,5-tetramethylcyclohexylidene)methyl]phenol;
 4-[[4'-(Methylsulfonyl)-4-biphenyl](3,3,5,5-tetramethylcyclohexylidene)methyl]phenol;
 5 (2E)-3-{4'-[(4-Hydroxyphenyl)(3,3,5,5-tetramethylcyclohexylidene)methyl]-3-biphenyl}-2-propenoic acid;
 4-[[4-(3-Pyridinyl)phenyl](3,3,5,5-tetramethylcyclohexylidene)methyl]phenol trifluoroacetate;
 10 3-{4-[(4-Hydroxyphenyl)(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl}propanoic acid;
 4-[(4,4-Dimethyl-cyclohexylidene)-(4-hydroxy-phenyl)-methyl]-benzoic acid;
 4-[Cycloheptylidene-(3-fluoro-4-hydroxy-phenyl)-methyl]-benzoic acid;
 3-{4-[Cycloheptylidene-(4-hydroxy-phenyl)-methyl]-3-fluoro-phenyl}-acrylic acid;
 15 N-{4-[(4-Hydroxy-phenyl)-(3,3,5,5-tetramethyl-cyclohexylidene)-methyl]-phenyl}-methanesulfonamide;
 N-{4-[(4-Hydroxy-phenyl)-(3,3,5,5-tetramethyl-cyclohexylidene)-methyl]-phenyl}-benzenesulfonamide;
 (2E)-3-{4-[Cycloheptylidene(4-hydroxyphenyl)methyl]-2-fluorophenyl}-2-propenoic
 20 acid;
 ((4-[Cycloheptylidene(4-hydroxyphenyl)methyl]phenyl)oxy)acetic acid;
 (2E)-3-{4-[cycloheptylidene(3-hydroxyphenyl)methyl]phenyl}-2-propenoic acid;
 (2E)-3-{4-[Cycloheptylidene (3-hydroxyphenyl)methyl]-2-fluorophenyl}-2-propenoic acid;
 25 4-{cycloheptylidene[4-(3-furanyl)phenyl]methyl}phenol;
 4-{Cycloheptylidene[4-(2-furanyl)phenyl]methyl}phenol;
 4-{cyclooctylidene[4-(2-furanyl)phenyl]methyl}phenol;
 4-{Cyclooctylidene[4-(3-furanyl)phenyl]methyl}phenol;
 4-{cyclooctylidene[4-(3,5-dimethyl-4-isoxazolyl)phenyl]methyl}phenol;
 30 4-{cycloheptylidene[4-(3,5-dimethyl-4-isoxazolyl)phenyl]methyl}phenol;
 4-[cycloheptylidene(4-hydroxyphenyl)methyl]benzonitrile;
 4-[(4-Hydroxyphenyl)(3,3,5,5-tetramethylcyclohexylidene)methyl] benzonitrile;
 (2E)-3-{4-[(4-Hydroxyphenyl)(2,2,6,6-tetramethyltetrahydro-4H-pyran-4-ylidene)methyl]phenyl}-2-methyl-2-propenoic acid;

- (2E)-3-{4-[cyclooctylidene(4-hydroxyphenyl)methyl]phenyl}-2-methyl-2-propenoic acid;
- {{4-[Cycloheptylidene(4-hydroxyphenyl)methyl]phenyl}oxy)acetonitrile;
- 4-{{4-[cycloheptylidene(4-hydroxyphenyl)methyl]phenyl}oxy)butanoic acid;
- 5 {{4-[(4-Hydroxyphenyl)(3,3,5,5-tetramethylcyclohexylidene) methyl] phenyl}oxy) acetic acid;
- 4-{{4-[(4-hydroxyphenyl)(3,3,5,5-tetramethylcyclohexylidene) methyl] phenyl}oxy)butanoic acid;
- 4-(Cycloheptylidene{4-[(2-hydroxyethyl)oxy]phenyl}methyl)phenol;
- 10 2-{{4-[Cycloheptylidene(4-hydroxyphenyl)methyl]phenyl}oxy)-2-methylpropanoic acid;
- 2-{{4-[(4-Hydroxyphenyl)(3,3,5,5-tetramethylcyclohexylidene) methyl phenyl] oxy)-2-methylpropanoic acid;
- {{4-[(4-Hydroxyphenyl)(3,3,5,5-tetramethylcyclohexylidene) methyl]phenyl}oxy)acetonitrile;
- 15 4-(Cycloheptylidene{4-[(2-hydroxy-1,1-dimethylethyl)oxy]phenyl}methyl) phenol;
- 4-[(4-Fluorophenyl)(3,3,5,5-tetramethylcyclohexylidene)methyl]phenol;
- {{4-[(4-fluorophenyl)(3,3,5,5-tetramethylcyclohexylidene)methyl] phenyl}oxy)acetic acid;
- 4-{{4-[(4-Fluorophenyl)(3,3,5,5-tetramethylcyclohexylidene) methyl]phenyl}oxy)
- 20 butanoic acid;
- {{4-[(4-Fluorophenyl)(3,3,5,5-tetramethylcyclohexylidene) methyl]phenyl} oxy) acetonitrile;
- 4-[[4-(3-Hydroxypropyl)phenyl](3,3,5,5-tetramethylcyclohexylidene) methyl] phenol;
- N-{4'-[(4-Hydroxy-phenyl)-(3,3,5,5-tetramethyl-cyclohexylidene)-methyl]-biphenyl-4-yl}-acetamide;
- 25 N-{4'-[(4-Hydroxy-phenyl)-(3,3,5,5-tetramethyl-cyclohexylidene)-methyl]-biphenyl-4-yl}-methanesulfonamide;
- 4-[[4-(3-furanyl)phenyl](3,3,5,5-tetramethylcyclohexylidene)methyl]phenol;
- 4-[[4-(3,5-dimethyl-4-isoxazolyl)phenyl](3,3,5,5-tetramethylcyclohexylidene) methyl]phenol;
- 30 4-[[4'-(4-morpholinyl)-4-biphenyl]yl](3,3,5,5-tetramethylcyclohexylidene)methyl]phenol;
- 3-fluoro-4'-[(4-hydroxyphenyl)(3,3,5,5-tetramethylcyclohexylidene)methyl]-4-biphenylcarbonitrile;
- 4'-[(4-hydroxyphenyl)(3,3,5,5-tetramethylcyclohexylidene)methyl]-4-biphenyl
- 35 carbonitrile;

4'-[cyclooctylidene(4-hydroxyphenyl)methyl]-4-biphenylcarbonitrile;
 4-{Cycloheptylidene[4-(5-hydroxy-1-pentyn-1-yl)phenyl]methyl}phenol;
 4-[[4-(3-hydroxy-3-methyl-1-butyn-1-yl)phenyl](3,3,5,5-tetramethyl
 cyclohexylidene)methyl]phenol;
 5 4-[[4-(4-hydroxy-1-butyn-1-yl)phenyl](3,3,5,5-tetramethylcyclohexylidene)
 methyl]phenol;
 5-{4-[(4-Hydroxyphenyl)(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl}-4-
 pentynoic acid;
 1-{4-[(4-Hydroxyphenyl)(3,3,5,5-tetramethylcyclohexylidene)methyl]phenyl}
 10 ethanone;
 4-[[4'-(Hydroxymethyl)-4-biphenyl]yl](3,3,5,5-tetramethylcyclohexylidene)
 methyl]phenol;
 4-[[3'-(Hydroxymethyl)-4-biphenyl]yl](3,3,5,5-tetramethylcyclohexylidene)
 methyl]phenol;
 15 4'-[(4-Hydroxyphenyl)(3,3,5,5-tetramethylcyclohexylidene)methyl]-2-
 biphenylcarboxylic acid; and
 4-[[2'-(Hydroxymethyl)-4-biphenyl]yl](3,3,5,5-tetramethylcyclohexylidene)
 methyl]phenol;
 including salts, solvates, and pharmacologically functional derivatives thereof.

20 26. A compound



including salts, solvates, and pharmacologically functional derivatives thereof.

27. The compound of claims 1 to 26 substantially as hereinbefore defined with reference to any one of the Examples.

25 28. A pharmaceutical composition comprising a compound according to claims 1 to 26, and a pharmaceutically acceptable carrier.

29. A compound according to claims 1 to 26 for use as an active therapeutic substance.

30. A compound according to claims 1 to 26 for use in the treatment or prophylaxis of conditions or disorders affected by selective estrogen receptor modulation.
- 5 31. The compound of claim 30 wherein treatment or prophylaxis relates to osteoporosis, bone demineralization, reduced bone mass, density, or growth, osteoarthritis, acceleration of bone fracture repair and healing, acceleration of healing in joint replacement, periodontal disease, acceleration of tooth repair or growth, Paget's disease, osteochondrodysplasias, muscle wasting, the maintenance and enhancement of muscle strength and function, frailty or
- 10 age-related functional decline ("ARFD"), sarcopenia, chronic fatigue syndrome, chronic myalgia, acute fatigue syndrome, acceleration of wound healing, maintenance of sensory function, chronic liver disease, AIDS, weightlessness, burn and trauma recovery, thrombocytopenia, short bowel syndrome, irritable bowel syndrome, inflammatory bowel disease, Crohn's
- 15 disease and ulcerative colitis, obesity, eating disorders including anorexia associated with cachexia or aging, hypercortisolism and Cushing's syndrome, cardiovascular disease or cardiac dysfunction, congestive heart failure, high blood pressure, breast cancer, malignant tumor cells containing the androgen receptor including breast, brain, skin, ovary, bladder, lymphatic,
- 20 liver, kidney, uterine, pancreas, endometrium, lung, colon, and prostate, prostatic hyperplasia, hirsutism, acne, seborrhea, androgenic alopecia, anemia, hyperpilosity, adenomas and neoplasia of the prostate, hyperinsulinemia, insulin resistance, diabetes, syndrome X, dyslipidemia, urinary incontinence, arteriosclerosis, libido enhancement, sexual
- 25 dysfunction, depression, depressive symptoms, nervousness, irritability, stress, reduced mental energy and low self-esteem, improvement of cognitive function, endometriosis, polycystic ovary syndrome, counteracting preeclampsia, premenstrual syndrome, contraception, uterine fibroid disease, and/or aortic smooth muscle cell proliferation, vaginal dryness, pruritis,
- 30 dyspareunia, dysuria, frequent urination, urinary tract infections, hypercholesterolemia, hyperlipidemia, peripheral vascular disease, restenosis, vasospasm, vascular wall damage due to immune responses, Alzheimer's disease, bone disease, aging, inflammation, rheumatoid arthritis, respiratory disease, emphysema, reperfusion injury, viral hepatitis,
- 35 tuberculosis, psoriasis, systemic lupus erythematosus, amyotrophic lateral

sclerosis, stroke, CNS trauma, dementia, neurodegeneration, breast pain and dysmenorrhea, menopausal or postmenopausal disorders, vasomotor symptoms, urogenital or vulvar vaginal atrophy, atrophic vaginitis, female sexual dysfunction, for enhancing libido, for the treatment of hypoactive sexual disorder, sexual arousal disorder, for increasing the frequency and intensity of orgasms, vaginismus, osteopenia, endometriosis, BPH (benign prostatic hypertrophy), dysmenorrhea, autoimmune diseases, Hashimoto's thyroiditis, SLE (systemic lupus erythematosus), myasthenia gravis, or reperfusion damage of ischemic myocardium.

- 5
- 10 32. The compound of claim 31 wherein treatment or prophylaxis relates to menopausal or postmenopausal disorders, vasomotor symptoms, urogenital or vulvar vaginal atrophy, atrophic vaginitis, endometriosis, female sexual dysfunction, breast cancer, depressive symptoms, diabetes, bone demineralization, or osteoporosis.
- 15 33. Use of a compound according to claims 1 to 26 in the manufacture of a medicament for use in the treatment or prophylaxis of conditions or disorders associated with selective estrogen receptor modulation.
- 20 34. Use of a compound according to any one of claims 1 to 26 in the manufacture of a medicament for use in the treatment or prophylaxis of osteoporosis, bone demineralization, reduced bone mass, density, or growth, osteoarthritis, acceleration of bone fracture repair and healing, acceleration of healing in joint replacement, periodontal disease, acceleration of tooth repair or growth, Paget's disease, osteochondrodysplasias, muscle wasting, the maintenance and enhancement of muscle strength and function, frailty or age-related functional decline ("ARFD"), sarcopenia, chronic fatigue syndrome, chronic myalgia, acute fatigue syndrome, acceleration of wound healing,
- 25 maintenance of sensory function, chronic liver disease, AIDS, weightlessness, burn and trauma recovery, thrombocytopenia, short bowel syndrome, irritable bowel syndrome, inflammatory bowel disease, Crohn's disease and ulcerative colitis, obesity, eating disorders including anorexia associated with cachexia or aging, hypercortisolism and Cushing's syndrome,
- 30 cardiovascular disease or cardiac dysfunction, congestive heart failure, high blood pressure, breast cancer, malignant tumor cells containing the androgen receptor including breast, brain, skin, ovary, bladder, lymphatic,
- 35 liver, kidney, uterine, pancreas, endometrium, lung, colon, and prostate,

prostatic hyperplasia, hirsutism, acne, seborrhea, androgenic alopecia, anemia, hyperpilosity, adenomas and neoplasia of the prostate, hyperinsulinemia, insulin resistance, diabetes, syndrome X, dyslipidemia, urinary incontinence, arteriosclerosis, libido enhancement, sexual dysfunction, depression, depressive symptoms, nervousness, irritability, stress, reduced mental energy and low self-esteem, improvement of cognitive function, endometriosis, polycystic ovary syndrome, counteracting preeclampsia, premenstrual syndrome, contraception, uterine fibroid disease, and/or aortic smooth muscle cell proliferation, vaginal dryness, pruritis, dyspareunia, dysuria, frequent urination, urinary tract infections, hypercholesterolemia, hyperlipidemia, peripheral vascular disease, restenosis, vasospasm, vascular wall damage due to immune responses, Alzheimer's disease, bone disease, aging, inflammation, rheumatoid arthritis, respiratory disease, emphysema, reperfusion injury, viral hepatitis, tuberculosis, psoriasis, systemic lupus erythematosus, amyotrophic lateral sclerosis, stroke, CNS trauma, dementia, neurodegeneration, breast pain and dysmenorrhea, menopausal or postmenopausal disorders, vasomotor symptoms, urogenital or vulvar vaginal atrophy, atrophic vaginitis, female sexual dysfunction, for enhancing libido, for the treatment of hypoactive sexual disorder, sexual arousal disorder, for increasing the frequency and intensity of orgasms, vaginismus, osteopenia, endometriosis, BPH (benign prostatic hypertrophy), dysmenorrhea, autoimmune diseases, Hashimoto's thyroiditis, SLE (systemic lupus erythematosus), myasthenia gravis, or reperfusion damage of ischemic myocardium.

35. Use of a compound as in claim 34 wherein the condition or disorder is menopausal or postmenopausal disorders, vasomotor symptoms, urogenital or vulvar vaginal atrophy, atrophic vaginitis, endometriosis, female sexual dysfunction, breast cancer, depressive symptoms, diabetes, bone demineralization, or osteoporosis.

36. A method for the treatment or prophylaxis of conditions or disorders associated with selective estrogen receptor modulation comprising the administration of a compound according to any one of claims 1 to 26.

37. A method for the treatment or prophylaxis of osteoporosis, bone demineralization, reduced bone mass, density, or growth, osteoarthritis, acceleration of bone fracture repair and healing, acceleration of healing in

joint replacement, periodontal disease, acceleration of tooth repair or growth, Paget's disease, osteochondrodysplasias, muscle wasting, the maintenance and enhancement of muscle strength and function, frailty or age-related functional decline ("ARFD"), sarcopenia, chronic fatigue syndrome, chronic myalgia, acute fatigue syndrome, acceleration of wound healing, maintenance of sensory function, chronic liver disease, AIDS, weightlessness, burn and trauma recovery, thrombocytopenia, short bowel syndrome, irritable bowel syndrome, inflammatory bowel disease, Crohn's disease and ulcerative colitis, obesity, eating disorders including anorexia associated with cachexia or aging, hypercortisolism and Cushing's syndrome, cardiovascular disease or cardiac dysfunction, congestive heart failure, high blood pressure, breast cancer, malignant tumor cells containing the androgen receptor including breast, brain, skin, ovary, bladder, lymphatic, liver, kidney, uterine, pancreas, endometrium, lung, colon, and prostate, prostatic hyperplasia, hirsutism, acne, seborrhea, androgenic alopecia, anemia, hyperpilosity, adenomas and neoplasia of the prostate, hyperinsulinemia, insulin resistance, diabetes, syndrome X, dyslipidemia, urinary incontinence, atherosclerosis, libido enhancement, sexual dysfunction, depression, depressive symptoms, nervousness, irritability, stress, reduced mental energy and low self-esteem, improvement of cognitive function, endometriosis, polycystic ovary syndrome, counteracting preeclampsia, premenstrual syndrome, contraception, uterine fibroid disease, and/or aortic smooth muscle cell proliferation, vaginal dryness, pruritis, dyspareunia, dysuria, frequent urination, urinary tract infections, hypercholesterolemia, hyperlipidemia, peripheral vascular disease, restenosis, vasospasm, vascular wall damage due to immune responses, Alzheimer's disease, bone disease, aging, inflammation, rheumatoid arthritis, respiratory disease, emphysema, reperfusion injury, viral hepatitis, tuberculosis, psoriasis, systemic lupus erythematosus, amyotrophic lateral sclerosis, stroke, CNS trauma, dementia, neurodegeneration, breast pain and dysmenorrhea, menopausal or postmenopausal disorders, vasomotor symptoms, urogenital or vulvar vaginal atrophy, atrophic vaginitis, female sexual dysfunction, for enhancing libido, for the treatment of hypoactive sexual disorder, sexual arousal disorder, for increasing the frequency and intensity of orgasms, vaginismus, osteopenia, endometriosis, BPH (benign

prostatic hypertrophy), dysmenorrhea, autoimmune diseases, Hashimoto's thyroiditis, SLE (systemic lupus erythematosus), myasthenia gravis, or reperfusion damage of ischemic myocardium.comprising the administration of a compound according to any one of claims 1 to 26.

- 5 38. The method of claim 37 wherein the condition or disorder is menopausal or postmenopausal disorders, vasomotor symptoms, urogenital or vulvar vaginal atrophy, atrophic vaginitis, endometriosis, female sexual dysfunction, breast cancer, depressive symptoms, diabetes, bone demineralization, or osteoporosis.